LB P8
Alternative Names: LB-P8Latest Information Update: 22 Apr 2024
At a glance
- Originator LISCure Biosciences; Novotech
- Developer LISCure Biosciences
- Class Bacteria; Hepatoprotectants
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Primary sclerosing cholangitis
- Phase I Cholestasis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis